Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint
BMS said the Phase 3 ALOFT-IPF trial met its primary lung-function endpoint at the 60 mg dose; complete results remain pending.
TL;DR
- Bristol Myers Squibb reported that Phase 3 ALOFT-IPF met its primary endpoint for admilparant in idiopathic pulmonary fibrosis.
- The company said the 60 mg twice-daily group had a statistically significant benefit in forced vital capacity change at Week 52 versus placebo.
- The topline release reported a favorable safety profile but did not supply a full peer-reviewed dataset.
Bristol Myers Squibb said on October 12 that its Phase 3 ALOFT-IPF trial met the primary endpoint for admilparant in adults with idiopathic pulmonary fibrosis. The study compared 60 mg and 120 mg doses, each given twice daily for at least 52 weeks, with placebo. [1] [2]
The company reported that the 60 mg group showed a statistically significant benefit in absolute change in forced vital capacity from baseline to Week 52 versus placebo. HCPLive’s separate coverage reports that the 120 mg dose slowed decline but did not reach statistical significance; the BMS release did not include the complete numerical results. [1] [2]
BioBriefs’ October 13 summary placed the result among same-day clinical developments and noted that the readout was mixed across BMS respiratory programs. The primary trial result remains a company topline disclosure, not a journal publication. [1] [2]
Further interpretation depends on complete effect estimates, secondary outcomes, and regulatory review. The available report does not establish approval or a change to clinical practice. [1] [2]
Why it matters
The result advances a Phase 3 candidate in a disease area with substantial unmet need, while the topline format limits independent assessment of clinical magnitude.
Editor's note
No treatment advice is offered. The BMS release is the primary source; BioBriefs provides separate coverage but the full trial dataset is not yet published.